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To determine the correlates of immune recovery from active human CMV (HCMV) disease, 
we compared the antigenic repertoire, diversity, magnitude, and differentiation of HCMV-
specific CD8
 
 
 
 T cells in HIV-HCMV coinfected subjects with no, cured, or active HCMV 
disease and in healthy HIV-negative HCMV-positive controls. ELISPOT–IFN-
 
 
 
 assays using 
peptide pools spanning the pp65 and immediate early 1 (IE1) HCMV proteins showed that 
HCMV-specific CD8
 
 
 
 T cells had a significantly broader antigenic repertoire and greater 
diversity in HIV-positive patients controlling HCMV replication than in those with active 
HCMV disease, but the magnitude of the CD8 T cell response did not differ between the 
different groups. HCMV-specific T cells mainly were focused against IE1 during the 
short-term recovery from retinitis, and switched toward pp65 during long-term recovery. 
HCMV-specific T cells displaying an “early” (CD8
 
 
 
CD27
 
 
 
CD28
 
 
 
) and “intermediate” 
(CD8
 
 
 
CD27
 
 
 
CD28
 
 
 
) differentiation phenotype were increased significantly during long-term 
recovery compared with other HIV-positive patients and were nearly undetectable during 
active HCMV disease. HCMV-specific T cells with a “late” (CD8
 
 
 
CD27
 
 
 
28
 
 
 
) differentiation 
phenotype predominated in all cases. Therefore, restoration of immune protection against 
HCMV after active HCMV disease in immunodeficient individuals is associated with enlarged 
repertoire and diversity, and with early differentiation of virus-specific CD8
 
 
 
 T cells, thus 
defining immune correlates of protection against diseases caused by persistent viruses.
 
Human cytomegalovirus (HCMV) is a common
pathogen that infects more than half of the
adult human population, but generally causes
only minor symptoms in immunocompetent
individuals (1). After initial exposure, healthy
individuals carry the virus as a latent infection
for life. Evidences for a major role of T cells in
the immune control of this persistent infection
are provided by the uncontrolled viral replica-
tion and HCMV end-organ diseases observed
in immunocompromised individuals with se-
verely impaired T cell functions, which make
the virus a major cause of morbidity and mor-
tality in this population.
Most HIV-infected patients are coinfected
with HCMV. In this population, retinitis—the
most frequent manifestation of severe uncon-
trolled HCMV reactivation—generally occurs
in the late stages of the T helper cell defi-
ciency. Although sensitive to anti-HCMV
therapy, retinitis usually relapses after discontinu-
ation of treatment if the CD4 T cell defects
persist (2, 3). The introduction of highly active
antiretroviral therapy (HAART) has changed the
frequency of HCMV end-organ diseases in
HIV-infected patients dramatically and its out-
come (4, 5). The immune reconstitution ob-
tained with HAART allows secondary anti-
HCMV prophylaxis to be discontinued safely
after at least 3 mo of successful HAART (4–6);
this suggests that a protective immunity to
HCMV has been restored, but correlates of
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immune protection against active HCMV (AHCMV) dis-
ease are still unknown.
HCMV-specific HLA class I–restricted T cell responses
are known to be essential for successful resolution of the in-
fection and maintenance of long-term control of HCMV
replication (7–10). Two HCMV proteins serve as key target
antigens for HCMV-specific T cells: a late matrix protein
(pp65) that is abundant throughout HCMV infection and an
immediate early 1 (IE1) antigen protein that is indispensable
for viral replication (1, 11).
The initial studies of antigen-specific CD8
 
 
 
 T cells re-
ported that IE1 was the main target for HCMV-specific T
cells (12), whereas subsequent studies found that they pre-
dominantly recognized pp65 (13–16). Experiments with
MHC class I tetramer/peptide complexes for direct ex vivo
measurement of the frequency of antigen-specific T cells
suggested that large numbers of specific CD8
 
 
 
 T cells that
focus against a limited set of immunodominant peptides
from pp65 (13, 17–20) and IE1 (21, 22) helped to control
HCMV replication. However, the latter studies may have
been biased by the selection of only a few epitopes for incor-
poration in tetramers. Recent reports revealed that cytokine-
producing T cells that are specific for HCMV recognize a far
broader repertoire of epitopes in healthy individuals (23, 24)
than previously believed, such as many epitopes from other
viral proteins (e.g., the pp28 and pp50 structural proteins,
gH and gB early/late proteins antigens, and HCMV-encoded
immunomodulators; reference 24). However, none of these
studies identified immune correlates of protection against
HCMV replication and of recovery after an acute HCMV
event.
Immune control of viral infections requires large num-
bers and an adequate repertoire of virus-specific MHC class
I–restricted T cells and their appropriate differentiation to
permit rapid effector function and survival potential. Studies
of human virus–specific T cells showed that the expression
of different combinations of the CD27 and CD28 costimula-
tory molecules on virus-specific CD8
 
 
 
 T cells correlates
with diverse differentiation and functional characteristics
(25–28).
A linear differentiation model was proposed for anti-
gen-experienced T cells with the CD27
 
 
 
CD28
 
 
 
 “early”
and CD27
 
 
 
CD28
 
 
 
 “intermediate” stages expressing low
or intermediate levels of perforin, respectively, and a
CD27
 
 
 
CD28
 
 
 
 “late” stage supposed to represent fully differ-
entiated effector T cells (28) because of their high perforin
content, ability to produce large amount of IFN-
 
 
 
 after stim-
ulation, and direct ex vivo mediation of cytotoxicity (25–30).
A general consensus (25–31) is that most HCMV-specific
CD8
 
 
 
 T cells in HCMV-infected individuals who do not
have AHCMV disease are CD27
 
 
 
CD28
 
 
 
CD57
 
 
 
CCR7
 
 
 
,
and this phenotype is believed to confer immune control.
Nonetheless, no study has addressed this question in immu-
nosuppressed patients who have HCMV end-organ disease or
after recovery from acute HCMV events, and the differentia-
tion stage of HCMV-specific T cells associated with restora-
tion of immune control has not been analyzed. The impact of
CD4 T helper cell defects, known to be key in the expansion
of memory T cells specific for viruses, is unknown.
The goal of this study was to characterize the HCMV-
specific CD8
 
 
 
 responses associated with restoration of a pro-
tective immunity after an acute HCMV event in patients
who were coinfected with HCMV and HIV, and to deter-
mine whether protective immunity against HCMV depends
on the antigenic repertoire, the diversity or magnitude of
specific CD8
 
 
 
 responses, or is associated with a particular
profile of CD8
 
 
 
 T cell differentiation (or any combination
of these elements).
We studied a group of HIV-HCMV–coinfected patients
who had suffered from an HCMV-retinitis when their CD4
counts decreased to 
 
 
 
50/mm
 
3
 
, in whom we previously
demonstrated that CD4 T cell reconstitution 
 
 
 
100/mm
 
3
 
 un-
der continuous HAART allowed discontinuation of the
HCMV prophylaxis and permanent control of the HCMV
disease (6). In this group, HCMV-specific CD8 responses
were studied 
 
 
 
2 yr (short-term recovery from retinitis;
STRR) and 
 
 
 
5 yr after stable recovery (long-term recovery
from retinitis; LTRR). They were compared with responses
observed in HIV-negative HCMV-infected healthy controls
and in two groups of HIV-HCMV–coinfected patients—
healthy (long-term nonprogressors; LTNPs) or suffering from
AHCMV disease. Analyzing the HCMV-specific CD8
 
 
 
 T
cells that produced IFN-
 
 
 
 after stimulation with synthetic
15-mer overlapping peptides spanning the two immunodom-
inant proteins, pp65 and IE1, enabled us to test exhaustively
each subject’s responses with the entire sequence of each pro-
tein without any predefined HLA-restriction, and to define
the magnitude, antigenic repertoire, and the diversity of the
HCMV-specific responses, as well as the differentiation stage
of the HCMV-specific CD8 cells involved.
 
RESULTS
Antigenic repertoire and diversity of the CD8
 
 
 
 T cell-
mediated HCMV-specific responses
 
We first identified the various antigenic regions (i.e., the anti-
genic repertoire) targeted by the HCMV-specific T cells that
produced IFN-
 
 
 
 in the ELISPOT assay by using pools of 15-
mer peptides covering all of the pp65 and IE1 sequences.
Overall, 10 of the 11 available pp65 peptide pools (91%)
and all 10 of the available IE1 peptide pools were recognized
at least once. CD8 cell depletion experiments showed that
the IFN-
 
 
 
 production induced by these pp65 and IE1 15-
mers was mediated primarily by CD8 T cells (unpublished
data). The pools were organized in a matrix to identify the
individual targeted peptides recognized by the 11 HIV-neg-
ative subjects. 20 individual peptides were recognized in 17
pools, with a mean of 1.2 peptides (range: 1–4) recognized
per pool. Considering the known HLA class I restriction of
previously described HCMV epitopes, this 15-mer overlap-
ping peptide pool organization reflected the actual epitope 
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repertoire recognized by the HCMV-specific T cells because
all of the pp65 and IE1 nonamers previously described were
recognized (unpublished data).
We then compared the antigenic repertoire of the pp65
and IE1 peptides recognized by CD8
 
 
 
 
 
T cells from HIV-
negative and HIV-positive subjects (Table I and Fig. 1).
Only 5 distinct pp65 pools induced at least one response
in the HIV-negative individuals: the pp65[251–310] and
pp65[351–561] regions (pools 6 to 11; i.e., the COOH-ter-
minal part of the protein). In contrast, PBMCs from HIV-
positive subjects who had controlled HCMV replication (i.e,
LTNPs, STRR, and LTRR subjects), recognized 10, 7, and
9 distinct pp65 pools, respectively, that covered the whole
pp65 sequence. Similarly, the HIV-negative donors recog-
nized only 4 IE1 pools, whereas LTNP, STRR, and LTRR
subjects recognized 7, 7, and 6 distinct IE1 pools, respec-
tively. Therefore, each distinct pp65 and IE1 pool was rec-
ognized by specific cells from a mean of 21% (range: 0–42%)
and 20% (range: 0–42%), respectively, of HIV-positive sub-
jects who had controlled HCMV replication, whereas a
mean of only 7% (range: 0–27%) of the HIV-negative indi-
viduals recognized each distinct pp65 and IE1 pool. In addi-
tion, considering patients who had AHCMV disease, each
distinct pp65 and IE1 pool was recognized by a mean of 10%
(range: 0–37%) and 6% (range: 0–25%) of patients. Thus, the
available HCMV antigenic repertoire engaged in CD8
 
 
 
 T
Figure 1. Broader antigenic repertoire of HCMV-specific CD8  T 
cell responses in HIV-positive subjects with controlled HCMV repli-
cation or recovering from AHCMV infection, compared with HIV-
negative (HN) healthy individuals and patients who had uncontrolled 
HCMV replication. The number of distinct pp65 and IE1 pools of peptides 
detected by ELISPOT assay at least once, by group. Each bar represents the 
number of persons whose CD8 T cells recognize each individual HCMV-
pp65 or IE1 peptide pool. 
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Table I.
 
Characteristics of study subjects
 
Subjects Age Sex HLA-I typing CD4 count Time from onset of episode of HCMV disease HCMV viral load
 
a
 
         months  
 
HN1
 
b
 
50 M A3/25 B18/35 no disease negative
HN2 48 M A2 B18/15 no disease negative
HN3 41 M A2/3 B7/18 no disease negative
HN4 36 F A2/25 B18/44 no disease negative
HN5 29 M A1/2 B8/57 no disease negative
HN6 44 M A1/29 B8/44 no disease negative
HN7 51 M A1/23 B44/61 no disease negative
HN8 45 M A1/23 B8/44 no disease negative
HN9 54 M A3/32 B18/47 no disease negative
HN10 40 M A24/28 B51/61 no disease negative
HN11 49 M A11/26 B12/40 no disease negative
LTNP1 43 M  694 no  disease negative
LTNP2 47 M 807 no disease negative
LTNP3 46 M 776 no disease negative
LTNP4 49 M 1500 no disease negative
LTNP5 41 F 1227 no disease negative
LTNP6 64 M 640 no disease negative
LTNP7 41 M 441 no disease negative
LTNP8 64 M 679 no disease negative
LTNP9 39 M 639 no disease negative
LTNP10 54 F 773 no disease negative
STRR1 57 M  194 17 negative
STRR2 41 M 490 20 negative
STRR3 56 M 425 20 negative
STRR4 41 M 366 20 negative
STRR5 56 M 241 17 negative
STRR6 55 M 348 22 negative
STRR7 49 M 194 17 negative
STRR8 50 M 490 20 negative
LTRR1 50 M  346
 
 
 
60 negative
LTRR2 47 M 483
 
 
 
60 negative
LTRR3 51 M 275
 
 
 
60 negative
LTRR4 45 M 361
 
 
 
60 negative
LTRR5 44 M 306
 
 
 
60 negative
LTRR6 55 M 344
 
 
 
60 negative
AHCMV1 43 M  5 active  retinitis positive
AHCMV2 36 M 5 active retinitis positive
AHCMV3 48 M 352 active retinitis positive
AHCMV4 33 M 17 active colitis positive
AHCMV5 41 M 50 active retinitis positive
AHCMV6 55 M 30 active retinitis positive
AHCMV7
 
b
 
53 M 121 active retinitis positive
AHCMV8
 
b
 
57 F  150 active  retinitis positive
 
a
 
Detection limit of 10 copies.
 
b
 
HIV-negative patient. 
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cell responses against pp65 and IE1 was significantly broader
among HIV-positive subjects who had controlled HCMV
replication than in healthy HIV-negative individuals (pp65,
P 
 
 
 
 0.010; IE1, P 
 
 
 
 0.010) and patients who did not con-
trol HCMV replication (pp65, P 
 
 
 
 0.045; IE1, P 
 
 
 
 0.006).
Taken together, these results suggest that HIV-infected in-
dividuals who control their HCMV infection, either spontane-
ously or after recovery of an AHCMV event, develop a broader
repertoire of HCMV-specific CD8 T cells against pp65 and IE1
than healthy HIV-negative subjects and severely immunosup-
pressed patients who are unable to control HCMV.
 
The diversity (number of peptide pools recognized per 
patient) of HCMV-specific CD8 T cell responses differs 
between HIV-negative and HIV-positive subjects
 
HIV-negative donors and patients who had AHCMV dis-
ease showed a limited diversity; they recognized a mean of
only 0.8 and 1.2 pp65 pools per subject in both groups, re-
spectively (range: 0–3 in both cases), and a mean of 0.7 and
0.6 IE1 pools, respectively (range: 0–2, in both cases). In
contrast, HIV-infected patients who had controlled HCMV
replication (LTNP, STRR, and LTRR) recognized a mean
of 2.3 pp65 pools per subject (range: 0–5) and a mean of 2
IE1 pools per subject (range: 0–5). When compared with
HIV-negative donors, patients who had controlled HCMV
replication showed a broader diversity against pp65 (P 
 
 
 
0.012) and IE1 (P 
 
 
 
 0.019), whereas the IE1 diversity (P 
 
 
 
0.025), but not the pp65 diversity (P 
 
 
 
 0.122), was greater
when compared with AHCMV retinitis.
Although the distribution of the HCMV peptides appar-
ently was balanced equally between pp65 and IE1 proteins in
all cases, the STRR subjects recognized significantly more
IE1 pools (P 
 
 
 
 0.001) than HIV-negative healthy subjects
and AHCMV subjects (P 
 
 
 
 0.001). In addition, LTNP (P 
 
 
 
0.020) and LTRR (P 
 
 
 
 0.034) subjects recognized signifi-
cantly more pp65 pools than HIV-negative healthy subjects
(Fig. 2).
These data suggest that immune control of HCMV repli-
cation in HIV-infected patients who are exposed to HCMV
is associated with enlarged repertoire and diversity of the
HCMV-specific CD8 cell responses. They also indicate that
restoration of protective immunity to HCMV seems to focus
on IE1 in the early period but switches toward pp65 in the
late immune restoration period, when it is similar to the
HCMV-specific immunity that is observed in LTNPs who
never had HCMV retinitis.
 
Magnitude of HCMV-specific CD8
 
 
 
 response
 
The magnitude of HCMV-specific T cell responses was
measured as the sum of the HCMV-specific T cells produc-
ing IFN-
 
 
 
 in response to the pp65 and the IE1 peptide
pools. Immunodominant peptides (i.e., the peptide pool
with the highest magnitude of response for each subject)
were distributed equally between pp65 and IE1 (49% pp65
and 51% IE1 pools).
The mean magnitude of HCMV-specific T cell re-
sponses among HIV-negative subjects was 580 spot-forming
cells (SFCs)/million PBMCs (range: 0–1,900) for pp65 and
471 SFCs/million PBMCs (range: 0–1,800) for IE1. Among
subjects who had AHCMV disease, the mean magnitude of
responses was 681 (range: 0–2480) and 973 SFCs/million
PBMCs (range: 0–3,900) for pp65 and IE1, respectively. In
line with the above results, magnitude of responses did not
differ significantly between HIV-infected patients who had
controlled HCMV replication (LTNP, STRR, and LTRR)
as a whole (mean: 1817, range: 0–9,200 and 2,430 SFCs/
million PBMCs, range: 0–7330 against pp65 and IE1, re-
spectively) and patients who had AHCMV disease (pp65,
P 
 
 
 
 0.332; IE1, P 
 
 
 
 0.115).
When analyzing each subgroup of HIV-positive patients
who had controlled HCMV replication, we found that the
LTNP and LTRR subjects did not differ from HIV-negative
individuals in the magnitude of their CD8 cell responses to
pp65 (LTNP, P 
 
 
 
 0.214; LTRR, P 
 
 
 
 0.097) and IE1
(LTNP, P 
 
 
 
 0.702; LTRR, P 
 
 
 
 0.059). In contrast, the
STRR subjects had significantly higher frequencies of CD8
cells directed against IE1 (P 
 
 
 
 0.001), but not against pp65
(P 
 
 
 
 0.709), than HIV-negative donors (Fig. 3). Notewor-
thy in STRR responders to IE1, each individual IE1 peptide
pool was recognized with a mean magnitude of 1699 SFCs/
million PBMCs, (range: 975–2350) that was significantly
Figure 2. Greater diversity of HCMV-specific CD8  T cell responses in 
HIV-positive subjects with controlled HCMV replication or recovering 
from AHCMV infection, compared with HIV-negative (HN) healthy 
individuals and patients who had uncontrolled HCMV replication. The 
number of distinct HCMV-pp65 and -IE1 pools of peptides detected by 
ELISPOT assay per individual. Each bar represents one individual; the number 
in bold type is the mean number of recognized pools per individual. 
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higher than that observed in HIV-negative responders (662
SFCs/million PBMCs, range: 165–1800; P 
 
 
 
 0.010); this
suggested an actual increase in the magnitude of response
against the HCMV-IE1 protein in this group. Thus, the im-
munodominant responses associated with immune protec-
tion appear to focus primarily against IE1 in the early period
of recovery from acute HCMV events. Finally, STRR sub-
jects showed significantly higher CD8 cell frequencies di-
rected against IE1 than did patients who had AHCMV dis-
ease (P 
 
 
 
 0.002; Fig. 3).
Therefore, our results suggest that although the diversity
and the magnitude of IE1-specific CD8 T cells explain in-
creased frequencies of IE1-specific CD8 T cells during the
early recovery period after HCMV retinitis, the magnitude
of the HCMV-specific response does not play a key role in
the long-term control of HCMV replication in HIV-infected
patients.
 
Differentiation of HCMV-specific CD8
 
 
 
 T cells
 
To study the differentiation characteristics of these CD8
 
 
 
HCMV-specific T cells, we selected the dominant peptide
pool recognized by each patient in the ELISPOT assay:
overall 75% were IE1. For each pool, we used an intracellu-
lar cytokine detection assay to analyze the simultaneous pro-
duction of IFN-
 
 
 
 and IL-2 in HCMV-specific CD8 cells.
Only IFN-
 
 
 
 production was observed with a mean of 0.78%
CD8
 
 
 
 cells producing IFN- ; we were unable to detect any
IL-2 production in those HCMV-specific T cells, even
when tested from HIV-negative, LTNP, or LTRR subjects
(unpublished data). Then we studied the coexpression of
CD27 and CD28 on the cell surface of CD8  T cells that
produced IFN-  against HCMV peptide pools, and quanti-
fied three subpopulations: CD27 CD28 , CD27 CD28 
and CD27 CD28  (Fig. 4). Changes in subset repartition
were observed among groups of patients for the CD27 28 ,
Figure 3. Magnitude of HCMV-specific CD8  T cell responses. The 
number of pp65 and IE1-specific IFN -producing T cells identified for 
each subject in ELISPOT assays. Each bar represents one subject. The num-
bers in bold type are the mean numbers of specific T cells per subject.
Figure 4. Differentiation profiles of HCMV-specific CD8  T cells. 
Flow-cytometry analysis of CD27 and CD28 coexpression gated on IFN- –
producing CD8 T cells after stimulation with the dominant HCMV peptide 
pool as detected in the ELISPOT assay. Each display represents results from 
a representative donor from each group. Proportions of cells in each 
quadrant are represented in the labels.JEM VOL. 201, June 20, 2005 2005
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CD27 28 , and CD27 28  cells, but not for the CD27 28 
subset.
The CD27 CD28 CD8  IFN-   T cell subpopulation
accounted for  72% of the HCMV-specific CD8  T cells,
and was the largest subpopulation for all groups of subjects
tested. In patients who had uncontrolled HCMV replication
(AHCMV),  90% of CD8  T cells displayed this late dif-
ferentiated stage. Similarly most HCMV-specific CD8  T
cells were CD57  (unpublished data). The percentages of
these cells were similar in LTRR subjects (72   12%) and
HIV-negative healthy individuals (76   12%). When ex-
pressed as numbers of T cells per million PBMCs per
subject  (Table II), only the counts of HCMV-specific
CD8  CD27 CD28  T cells observed in patients who had
AHCMV (P   0.032) were significantly higher than in
HIV-negative subjects, whereas those from LTNP (P  
0.286), STRR (P   0.065), or LTRR (P   0.095) subjects
were not.
These results show that patients who are exposed to high
levels of HCMV replication at advanced stages of CD4 im-
munodeficiency had maintained greater numbers of “late”
differentiated HCMV-specific CD8  T cells than patients
Table II. Distinct pattern of differentiation of HCMV-specific CD8  T cells associated with long-term immune recovery
Frequencies of HCMV-specific T cells Subsets of HCMV-specific CD8  T cells producing IFN a
Subjects HCMV pool tested SFC/M PBMCb CD8 IFN- c CD27 CD28  CD27 CD28  CD27 CD28 
%% N d %N d %N d
HN3 IE1-4 440 54 90 214 2.6 6 3.7 9
HN4 IE1-8 1,300 79 71.9 738 1.1 11 16.8 173
HN7 IE1-8 500 71 63.4 225 7.3 26 19.5 69
HN9 IE1-4 500 63 67.3 212 3.6 11 25.4 80
HN11 IE1-1 1,800 93 88.6 1,483 1.5 25 5.3 89
mean 908 72 76.2 574 3.2 16 14.1 84
LTNP3 pp65-5 1,240 30 73.5 273 4 15 2 7
LTNP6 IE1-1 1,600 71 95 1,080 1.2 14 2.5 28
LTNP7 IE1-4 1,650 79 88.1 1,148 1.1 14 4.5 58
LTNP8 IE1-2 1,330 78 85.7 889 0.5 5 3.2 33
mean  1,450 64 85.6 847 1.7 12 3 31
STRR1 IE1-4 3,000 70 93.4 1,961 0.8 17 0.3 6
STRR2 IE1-2 3,000 50 78.2 1,173 1.7 26 0.7 11
STRR3 IE1-5 1,800 51 92.4 848 0.3 3 2.3 21
STRR4 IE1-7 3,000 66 92.5 1,831 1.3 26 0.7 14
STRR5 pp65-6 1,000 43 68 293 5.6 24 13 56
STRR6 pp65-5 910 30 78.6 215 9 25 9 25
STRR7 IE1-7 3,000 74 88 1,954 1.4 31 1.1 24
STRR8 IE1-7 3,000 72 86.9 1,877 1.5 32 2 43
mean 2,338 57 84.7 1,269 2.7 23 3.6 25
LTRR1 pp65-9 3,000 69 61.3 1,269 1.7 35 8.8 182
LTRR2 IE1-7 3,000 95 67.9 1,935 3.6 102 9.1 260
LTRR3 pp65-6 3,000 75 88.6 1,993 2.6 58 6.1 137
LTRR5 IE-4 620 61 81.5 306 6.1 23 9.2 35
LTRR6 IE1-5 2,000 81 62.5 1,251 5.3 106 23.8 476
mean 2,324 76 72.4 1,351 3.9 65 11.4 218
AHCMV1 pp65-8 3,000 85 91.2 2,325 1 26 0.8 20
AHCMV3 IE1-4 1,900 91 93.3 1,613 0.6 11 2.9 50
AHCMV4 IE-7 1,370 97 96.8 1,286 0.3 4 0.3 4
AHCMV7 IE1-5 2,330 80 90 1,677 0.6 11 0.8 15
mean  2,150 88 92.8 1,725 0.6 13 1.2 22
aAssessed by intracellular cytokine staining.
bAssessed by ELISPOT assay.
c%CD8   IFN-     number of CD8 -producing IFN- /number of PBMCs producing IFN-  as assessed by intracellular cytokine staining.
dN   %CD27CD28   (SFCs/M. PBMC   %CD8 IFN-  ).CORRELATES OF PROTECTIVE IMMUNITY AGAINST HCMV | Sacre et al. 2006
who were recovering from retinitis (STRR, LTRR) and pa-
tients who never experienced AHCMV disease (LTNP,
healthy HIV-negative donors).
In addition, the proportions of “early” differentiated
HCMV-specific CD27 CD28 CD8  T cells were signifi-
cantly higher during the late recovery period (LTRR, 11  
7%) than among the other HIV-infected patients (LTNP,
3.0   1.2%, P   0.016; STRR, 3.6   4.7%, P   0.042;
AHCMV, 1.2   1.2%, P   0.016), but were identical to the
proportions observed in the HIV-negative group (14   9%,
P   1.000). The patients who had AHCMV disease had the
lowest percentages of CD27 CD28 CD8  T cells. The
mean numbers of CD27 CD28 CD8  T cells in LTRR
subjects were likewise significantly higher than in the other
HIV-infected patients (LTNP, P   0.032, STRR, P  
0.006, AHCMV, P   0.032).
Furthermore, recovery of HCMV-specific immunity by
LTRR subjects also was associated with the reinforcement
of the “intermediate” differentiated subpopulation of
CD27 CD28 CD8  T cells. The mean number of these
cells was significantly higher in these patients than in the
other HIV-infected groups (LTNP: P   0.016; STRR: P  
0.041; AHCMV: P   0.032).
These results suggest that long-term immune restoration
after several years of HAART was associated with a regener-
ation of new early and intermediate CD28 CD8  T cells
(i.e., differing only according to the presence of CD27),
which had almost disappeared during the acute HCMV
events.
DISCUSSION
Our findings show that restoration of an immune control af-
ter AHCMV disease in HIV-infected patients is associated
with enlarged antigenic repertoire and diversity of HCMV-
specific CD8  responses, and with regeneration of “early”
and “intermediate” differentiated CD27 / CD28 CD8 
HCMV-specific T cells. In addition, focusing CD8  T cell
responses against the IE1-HCMV protein during the early
recovery period also seems to be an essential feature of im-
mune recovery.
The exhaustive and systematic analysis of the HCMV-
pp65 and -IE1 CD8 cell recognition that we performed—
combining 15-mer peptide pools and ELISPOT–IFN- 
assays—provided the same magnitude of anti-pp65 and anti-
IE1 CD8 cell responses in healthy HIV-negative subjects as
was described recently by using preselected HLA-matched
optimal 9-mer epitopes (24). The repertoire of HCMV pep-
tides available for CD8  T cell recognition defined with our
strategy also is consistent—considering HLA class-I haplo-
types—with all HCMV epitopes described in the literature
(10, 14, 23, 24, 32). Lack of response in two healthy HCMV
carriers might suggest that HCMV-specific T cells can be di-
rected against non-pp65 and non-IE1 proteins (24) or that
this portion of the pp65 protein is poorly immunogenic. Al-
though the HLA haplotypes of our HIV-negative donors are
representative of a typical HLA class I Caucasian distribu-
tion, some MHC bias might explain the lack of response in
HIV-negative subjects against the five N-proximal pp65
[1–260] pools, rather than a lack of immunogenicity of this
Figure 5. Immune correlates of a stable recovery after AHCMV retinitis. A model based upon the experimental findings is proposed.JEM VOL. 201, June 20, 2005 2007
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region because it is recognized in HIV-infected subjects or
published data (16, 20, 23, 24, 33).
Our study substantiates that the magnitude of the
HCMV-specific responses does not play a key role in con-
trolling HCMV replication, and is not sufficient to ensure
protection against AHCMV disease. In contrast, antigenic
repertoire and diversity of HCMV-specific CD8  T lym-
phocytes that produce IFN-  are key correlates of restora-
tion of an immune control of HCMV and of protection
against relapses of HCMV retinitis. The broad antigenic rep-
ertoire and diversity of HCMV-specific responses clearly dif-
fered from those that were observed in healthy HCMV-pos-
itive patients and in subjects who were unable to control
HCMV replication.
One likely hypothesis is that a high level of HCMV rep-
lication in HIV-infected patients exposes the immune system
to a broad repertoire of HCMV epitopes which can be rec-
ognized adequately by CD8 T cells only when CD4 help is
present at sufficient levels. We previously reported in the
RESTIMOP study (6), from which the STRR and LTRR
subjects were drawn, that HAART initiation in patients
who were recovering from retinitis was associated with re-
stored CD4 counts and CD4 proliferative responses to
HCMV. Similarly, a recent study pointed out the role of the
CD4 help in primary HCMV infection (34). Our results and
hypothesis also are consistent with murine models which
showed that CD4 help ensures the maintenance and com-
petitive fitness of virus-specific memory CD8 T cells (35,
36). Although characteristics of immune response to HCMV
observed 17 mo to 60 mo or longer after an AHCMV dis-
ease might result from a major exposure to high HCMV
viremia during such disease, HCMV remained undetectable
in all recovering patients during the entire study period. Fur-
thermore, it was shown that HCMV viremia was cleared 3
mo after initiation of HAART (37–39). Finally, severe un-
controlled HCMV reactivation generally occurs at late stages
of the T helper cell deficiency when CD4 counts decrease to
 75/mm3 (2), and secondary anti-HCMV prophylaxis can
be discontinued safely only when CD4 counts are restored
to  100/mm3 after introduction of HAART (4–6). There-
fore, we propose that exposure to high HCMV viremia in
the absence of help does not allow the characteristics of the
immune responses that we observed after recovery of AH-
CMV disease, which require in addition a restored help.
Thus, the strength of the antigenic pressure—defined as
numbers of viral epitopes produced—and the available help
determine the repertoire and the diversity, and thereby, the
immune control of AHCMV replication and disease.
In addition, recovery from acute HCMV retinitis is asso-
ciated with immunodominance of the IE1-HCMV antigen
during the first 2 yr after retinitis, whereas pp65 might be
more instrumental in the long term. A protective role of
IE1-specific CD8 T cells was recognized recently in HIV-
negative patients who had AHCMV disease (40). Changing
patterns of CD8  T cell immunodominance have been
demonstrated in murine models of influenza virus infection
and were shown to reflect the antigen density in antigen-
presenting cells, the T cell repertoire available, and the dif-
ferential antigen presentation in the course of the virus infec-
tion (41, 42). The dominant IE1 response that we observed
might not reflect differences in amounts of IE1 and pp65
proteins because both are produced equally by cells replicat-
ing HCMV, but rather might reflect a different kinetics of
production. IE1 is the first HCMV protein to be expressed
during the virus cycle and can block apoptosis before other
HCMV proteins that can block antigen processing and pre-
sentation selectively (1). Thus, presentation of IE1 might be
favored in AHCMV replication and polarize the immune re-
sponses toward IE1, but might decrease progressively when
HCMV replication is controlled durably, and thus, allows
the balance between pp65 and IE1 to be restored.
According to the current consensus (25, 31, 43), we
show that most CD8  T cells that are engaged against
HCMV have a CD27 CD28 CD57  phenotype in healthy
HIV-negative and HIV-positive individuals. CD57 and
CD28 expression (mutually exclusive in CD8  T cell popu-
lations; references 26, 44–47) is associated with terminal dif-
ferentiation of antigen-experienced T cells that have under-
gone numerous cell divisions and are unable to proliferate
(replicative senescence). These features might reflect the
continuous stimulation of specific CD8  T cells by HCMV
antigens over years. The findings from patients who
have AHCMV disease suggest that the predominant
CD27 CD28 CD57  differentiation profile, as well as the
magnitude of those cells, is not sufficient to control HCMV
replication if not associated with a broad repertoire of
HCMV-specific cells in an earlier differentiation profile.
The reinforcement of the HCMV-specific CD27 / 
CD28 CD8  T cells, after recovery from retinitis to levels
similar to those observed in healthy individuals, suggests that
these cells, with a known higher proliferation ability (25, 31,
48), play a key protective role in ensuring stable control of
HCMV replication. The regeneration of these subsets after
HCMV retinitis and their long-term maintenance may de-
pend on CD4 help, as suggested by studies demonstrating
the need for CD4 help in maintaining effective cytotoxic T
lymphocyte responses (49), and the importance of IL-2 pro-
duction in virus-specific T cells in HIV-infected patients (50,
51). We were unable to detect any IL-2 production in those
HCMV-specific T cells, even when tested from HIV-nega-
tive LTNP or LTRR subjects (unpublished data). Thus, re-
covery—with antiretroviral treatments—of an efficient CD4
help may to make it possible to restore these key subsets.
Finally, a scheme for immune control of HCMV can be
drawn from these findings (Fig. 5). In healthy individuals
with a normal CD4 help, a low level HCMV replication
maintains a weak activation of HCMV-specific CD8  T
cells equally balanced against pp65 and IE1 antigens. Those
HCMV-specific cells are composed of a mixed population of
“early” and “intermediate” CD27 / 28  cells that perma-CORRELATES OF PROTECTIVE IMMUNITY AGAINST HCMV | Sacre et al. 2008
nently give rise to “late” CD27 28  effector cells, and thus,
establish a quasi-equilibrium between controlled virus reacti-
vation and host defenses. If HCMV replication increases
slightly, as observed in concurrent HIV infection, the reper-
toire and diversity of HCMV-specific CD8 T cells broaden,
as long as the CD4 help persists, with a mixed phenotype
but an accelerated conversion toward “late” cells. If the CD4
help disappears, new early or intermediate HCMV-specific
cells cannot regenerate and the repertoire cannot broaden;
the remaining “late” HCMV-specific cells cannot control
the outgrowth of the virus, even if in large numbers, and ac-
tive disease occurs. Control of AHCMV disease takes place
only when a strong CD4 help is restored and involves a
broadening of the repertoire and diversity of the HCMV-
specific CD8 T cells against IE1. If CD4 help is maintained
over time, regeneration of “early” and “intermediate”
CD27 / 28  phenotypes occurs that will ensure long-term
protection and a quasi-healthy equilibrium.
Such key associations between antigenic repertoire, di-
versity, differentiation of HCMV-specific CD8 T cells, and
restoration of an immune control of AHCMV disease also
might apply to other immune deficiencies that expose carri-
ers to HCMV reactivation and disease. If so, our results may
provide a model for defining immune correlates of long-
term protection against other persistent viruses, such as HIV.
MATERIALS AND METHODS
Patients. PBMC samples that were frozen and stored as described below
were obtained from 38 HCMV-infected individuals. The HCMV infection
was determined by serologic status. Samples from 11 HCMV-positive
healthy HIV-negative blood bank donors for whom HLA class I haplotype
was known come from a kind collaboration with E. Robinet (Etablissement
Français du Sang, Besançon, France). A series of 30 HCMV-positive HIV-
infected patients were classified into three groups according to clinical sta-
tus. The first group was made up of 10 LTNPs from the French Asymp-
tomatiques à Long Terme cohort reported elsewhere with the following
characteristics: HIV diagnosis for  8 yr; normal CD4  T lymphocytes
 600/mm3 at inclusion; no antiretroviral treatment; and no HIV-related
symptoms, especially no history of AHCMV disease and undetectable
HCMV viremia (52). The second group consisted of 14 HAART-treated
patients who were enrolled in the RESTIMOP clinical trial (6) after recov-
ery from an episode of HCMV retinitis that had occurred before the
HAART era and was cured under anti-HCMV therapy followed by
HAART, and who discontinued secondary anti-HCMV prophylaxis when
their CD4 counts had reached a threshold of 75/mm3. All remained with-
out anti-HCMV secondary prophylaxis during follow-up without subse-
quent progression of retinitis during the study; they were monitored care-
fully by ophthalmologic examinations. Classification of these 14 patients
into two subgroups was based on length of postretinitis HAART: a group
with STRR (n   8) who had been receiving HAART for  2 yr and a
group with LTRR (n   6) who had been receiving HAART for  5 yr.
The third group contained 8 patients who had AHCMV disease: 6 HIV-
infected individuals (2 naive of HAART and 4 with uncontrolled HIV rep-
lication despite HAART) and 2 non-HIV infected individuals who had se-
vere CD4 immunodeficiency (one had Good’s syndrome [AHCMV7] and
one had an idiopathic CD4 lymphopenia [AHCMV8]). All patients in this
group had an HCMV retinitis except one who had an HCMV colitis. All
clinical samples were obtained according to ethical rules after agreement
from institutional review boards. All subjects provided written informed
consent. All patients except for the 8 in the third group had undetectable
HCMV viral loads. HCMV PCR was performed with the HS ELOSA
CMV kit (Lambdatech), which has a detection limit of 10 copies/ml. Table
2 summarizes the characteristics of the study patients.
PBMC preparation and storage. PBMCs were obtained after separa-
tion with a standard Ficoll-Hypaque gradient (Pharmacia) separation on
fresh blood samples and immediate cryopreservation in FCS (GIBCO BRL,
Life Technology) containing 10% DMSO (Merck) in liquid nitrogen. Try-
pan blue exclusion after thawing showed a mean viability of 85%.
Peptides. The synthetic peptides were 15 amino acid–long peptides over-
lapping by 10 amino acids and spanning the two HCMV proteins, pp65 and
IE1, according to EPYTOP (53) and obtained from the INSERM “Action-
Thematique-Concertée on antiviral immunity.” A total of 110 pp65 peptides
were clustered in 11 pools of 10 contiguous peptides (pp65 pools 1–11), and
96 IE1 peptides were clustered in 8 pools of 10 contiguous peptides (IE1
pools 1–8) and in 2 pools of 8 contiguous peptides (IE1 pools 9 and 10). Each
pool covered a sequence of 59 amino acids, except IE1 pools 9 and 10, which
covered sequences of 49 amino acids and 50 amino acids, respectively.
ELISPOT assay. The ELISPOT assay was adapted from a previously de-
scribed method (54). In brief, 96-well nitrocellulose plates (Multiscreen Im-
mobilon-p Filtration Plates, Millipore) were coated with human monoclo-
nal anti–IFN-  IgG1 (Mabtech). After three washings and blockage with
10% FCS, PBMCs were added at a concentration of 105 in triplicate wells
for each experimental condition. Pools of overlapping 15-mer peptides
spanning HCMV pp65 and HCMV IE1 (100  l at a final concentration of
2  g/ml), RPMI 1640  (negative control), or PHA (GIBCO BRL) (con-
trol antigen) were added to the appropriate wells; the plates were incubated
for 18 h at 37 C in a 5% CO2 atmosphere and then washed. A biotinylated
detection antibody, anti–IFN-  (Mabtech), was added and incubated at
37 C for 4 h and, after washings, followed by the addition of streptavidin-
alkaline phosphatase (Amersham Biosciences), substrate, and incubation at
room temperature. SFCs were counted using an automated ELISPOT
reader (Carl Zeiss MicroImaging, Inc.). Results were expressed as the mean
number of SFCs/106 PBMC (SFC/M) in each experimental condition after
subtraction of the mean negative control values. All peptide pools that in-
duced IFN-  response  50 SFCs/M above background were considered
putative CD8  T cell epitopes. Saturated responses were counted arbitrarily
as responses of 3,000 SFCs/M.
The cell origin of this IFN-  production was assessed in 11 HIV-nega-
tive individuals by reevaluating positive responses against peptide pools on
CD8 -depleted PBMCs after using CD8 magnetic beads (Dynal). Each
pool was tested with total and CD8 -depleted PBMCs. A mean of 81% in-
hibition of recognition was obtained with CD8 -depleted PBMCs assessing
the predominant CD8 cell involvement (unpublished data). In HIV-
infected patients, the predominant CD8 cell origin of the HCMV-specific
IFN-  production was assessed by intracellular cytokine staining.
Cell surface and intracellular staining by flow cytometry. The as-
say was adapted from a previously described method (32, 46, 53, 55, 56). 1
million PBMCs were incubated for 6 h in the presence of peptide pools de-
tected as epitopes in the ELISPOT assay at the final concentration of 2  g/
ml, control antigen (PHA; GIBCO BRL), or RPMI 1640  (negative con-
trol). Brefeldin A (Sigma-Aldrich) was added to the culture for the final 4 h.
After washings, PBMCs were incubated for 15 min at room temperature
with the following fluorescent-labeled conjugated monoclonal antibodies:
anti-CD4–FITC, anti–CD8-PerCP, anti–CD27-PE or FITC, and anti–
CD28-FITC or PE (all Becton Dickinson). After washings, cells were fixed
with buffered formaldehyde acetone solution and permeabilized with 0.1%
saponin, 50 mM D-glucose. Cells were incubated, stained with anti–IFN- -
APC or anti–IL-2-PE (BD Biosciences), washed, and fixed in PBS 1X –
0.5% BSA. Flow cytometric analysis was performed immediately using a
FACScalibur (Becton Dickinson). Data files contained 75,000 events positive
for CD8-PerCP fluorescence per lymphocyte gate. The frequency of IFN-JEM VOL. 201, June 20, 2005 2009
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   cells within each CD8  lymphocyte gate was assessed with Cellquest soft-
ware (Becton Dickinson); results were considered positive if  0.1% of the
CD8  cells within the CD8  gate were IFN- –positive after the negative
control values were subtracted. A mean of 68   18% CD8 cells was found to
be responsible for the IFN-  production within lymphocytes.
Statistical analysis. Exact nonparametric two-tailed tests from SPSS
12.0.1.0 for windows from SPSS Inc. were used. The Wilcoxon signed-
rank test was used to compare the frequency of recognition of each pool,
and the nonparametric Mann-Whitney test was used to analyze differences
between the groups. P   0.05 was considered to be statistically significant.
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